High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy:A prospective longitudinal study

Röhrl, Kari; Guren, Marianne G.; Astrup, Guro Lindviksmoen; Småstuen, Milada Cvancarova; Rustøen, Tone

doi:10.1016/j.ejon.2019.101679

Cited by 24 publications

(25 citation statements)

References 181 publications

(328 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With advancements at the medical level, the survival time of cancer patients is continuously prolonged, and cancer is listed as a chronic disease by the WHO. An increasing number of studies have begun to focus on the symptom burden of cancer patients (Fjell et al, 2020; Ooki et al, 2020; Rohrl et al, 2020). The symptom burden not only reduces the patient's quality of life but may also lead to interruption or delay in treatment (Deshields et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Hope and symptom burden of women with breast cancer undergoing chemotherapy: A cross‐sectional study

Zhou

et al. 2021

Journal of Clinical Nursing

View full text Add to dashboard Cite

Aim This research aimed to explore the level of hope and symptom burden of breast cancer women undergoing chemotherapy, and predictive factors of hope were also investigated. Background Chemotherapy brings physical and psychological stress to breast cancer patients. As an effective coping strategy, hope gives them the courage to overcome difficulties and improve prognosis and survival. Therefore, efforts are needed to raise hope. Design/Methods A total of 450 women who were undergoing breast cancer chemotherapy participated in this cross‐sectional study. Sociodemographic data, disease characteristics, and measures of hope and symptom burden were collected using questionnaires. Hope was assessed using the validated Herth Hope Index, and the previously validated Memorial Symptom Assessment Scale was used to assess symptom burden. This paper adhered to the STROBE guidelines. Results Chinese breast cancer chemotherapy women hope average scores of 30.15 ± 4.82 were in the medium range of the Hearth Hope Index as specified by Herth to be 24–35. Patients with age ≤45, religious beliefs and lighter symptom burden have a higher level of hope. These variables explained a total of 22.9% of the variation in hope. Conclusions The level of hope for women undergoing breast cancer chemotherapy still needs to be further improved. Symptom burden can negatively predict hope. Relevance to clinical practice If nurses can decrease breast cancer chemotherapy women symptom burden, there is an impact on increasing levels of hope.

show abstract

Section: Introductionmentioning

confidence: 99%

Hope and symptom burden of women with breast cancer undergoing chemotherapy: A cross‐sectional study

Zhou

et al. 2021

Journal of Clinical Nursing

View full text Add to dashboard Cite

show abstract

“…Although survival continues to increase for those with a cancer diagnosis, 27 it is important that the QOL during this time is also considered 28 . The importance of diagnosing and treating cancer‐related malnutrition and poor muscle strength does not end once an individual is discharged from hospital but rather should continue throughout cancer survivorship, thereby helping to improve health and QOL at the same time as reducing the risk of developing additional co‐morbidities such as cardiovascular disease 29 …”

Section: Introductionmentioning

confidence: 99%

Female cancer survivors are more likely to be at high risk of malnutrition and meet the threshold for clinical importance for a number of quality of life subscales

Keaver

O’Callaghan

O'Sullivan

et al. 2021

J Human Nutrition Diet

View full text Add to dashboard Cite

Background The present study aimed to explore malnutrition risk, handgrip strength and quality of life (QOL) in cancer survivors. Methods In total, 232 individuals completed a demographic questionnaire, Patient‐Generated Subjective Global Assessment Short Form and the European Organization for Research and Treatment of Cancer QOL Questionnaire (EORTC QLQ‐C30). Handgrip strength was determined using a spring‐loaded handgrip dynamometer and anthropometric measurements were taken by an oncology nurse. Frequencies and distribution data, analysis of variance and chi‐squared tests were then conducted. Results The majority of the cohort were female (n = 141; 60.8%) had breast cancer (n = 62; 26.7%) and the mean ± SD body mass index (BMI) was 26.6 ± 6.2 kg m–2. Less than a one‐third reported seeing a dietitian (n = 68; 29.3%). Over one‐third reported recent weight loss (n = 88; 37.3%). Some 40.9% (n = 95) were at moderate to high risk of malnutrition, with women more likely than men to be classified as high risk (p < 0.05). Mean ± SD handgrip strength was 25 ± 15 kg and this differed significantly by gender (p = 0.00), cancer type (p = 0.01) and BMI classification (p = 0.01). One‐fifth of individuals were classified as having dynapenia (n = 48; 21.1%). Median (interquartile range) QOL score was 66.7 (33.3). The proportion of individuals meeting the threshold for clinical importance for QOL subscales ranged from 12.5% (constipation) to 42.7% (physical functioning). Females were more likely than males to meet the threshold for physical functioning (p = 0.00), fatigue (p = 0.02) and pain (p = 0.01). Conclusions Females are more likely than males to be at high risk of malnutrition and meet the threshold for clinical significance for several QOL subscales.

show abstract

“…In conclusion, compared with a single symptom, the symptom clusters will significantly reduce the functional status and quality of life of CRC survivors, thus deteriorating patient outcomes (3). By identifying postoperative chemotherapy-related symptom clusters in CRC patients (or symptom cluster indicators), clinicians can better understand CRC patients' experience, and ultimately provide better clinical nursing, thus improving patient compliance with cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Although postoperative adjuvant chemotherapy has been shown to prolong disease-free survival of radical resected CRC patients, it promotes side effects in many survivors of CRC, often not a single symptom but including fatigue, restless sleep, nausea, vomiting, numbness, and other symptoms (2). These grouped symptoms have a great impact on the quality of life of CRC patients (3).…”

Section: Introductionmentioning

confidence: 99%

Serum biomarkers predict adjuvant chemotherapy-associated symptom clusters in radical resected colorectal cancer patients

Li¹,

Lu²,

Xia³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Due to individual heterogeneity, patients at the same stage of colorectal cancer (CRC) who receive the same chemotherapy may experience different symptom clusters. Identifying the precise factors that predict symptom clusters is of great clinical significance for precision care and for improving the quality of life of patients. The present study investigated the relationship between serum biomarkers and adjuvant chemotherapy-related symptom clusters in radically resected CRC patients. Methods: Serum biomarkers and clinical/pathological characteristics of the radical resected CRC patients were collected before the first cycle of adjuvant chemotherapy. A demographic questionnaire and M.D.Anderson Gastrointestinal Cancer Symptom Scale (MDASI-GI) were performed on the third day after chemotherapy and exploratory factor analysis was performed to determine the symptoms clusters. Multiple linear regression and correlation analysis were also performed to evaluate the correlation between serum biomarkers and chemotherapy-related symptom clusters.Results: A total of 4 chemotherapy-related symptom clusters were determined in the enrolled radical resected CRC patients, including a fatigue-psychological symptom cluster, gastrointestinal symptom cluster, neurotoxic symptom cluster, and constipation-abdominal distension symptom cluster. Further analysis showed that the gastrointestinal symptom cluster was significantly associated with age, gender, weight change status, neutrophil to lymphocyte ratio (NLR), and body mass index (BMI). Additionally, the fatiguepsychological symptom cluster was found to be significantly associated with high NLR. The neurotoxic symptom cluster was found to be significantly associated with low hemoglobin level.Conclusions: Serum biomarkers and clinical characteristics of the radical resected CRC patients could be used to predict chemotherapy-related symptoms clusters.

show abstract

High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy:A prospective longitudinal study

Cited by 24 publications

References 181 publications

Hope and symptom burden of women with breast cancer undergoing chemotherapy: A cross‐sectional study

Hope and symptom burden of women with breast cancer undergoing chemotherapy: A cross‐sectional study

Female cancer survivors are more likely to be at high risk of malnutrition and meet the threshold for clinical importance for a number of quality of life subscales

Serum biomarkers predict adjuvant chemotherapy-associated symptom clusters in radical resected colorectal cancer patients

Contact Info

Product

Resources

About